Semax
Women's HealthCycle-aware, fertility-aware, perimenopause-aware: Semax is evaluated by women's-health clinicians on multiple axes. Elevates BDNF and NGF in hippocampus and cortex Modulates dopamine and serotonin transporter expression. Inhibits enkephalinase, indirectly extending endogenous enkephalin action. Approved in Russia for stroke rehabilitation and cognitive disorders.. The compound's acth-derived nootropic heptapeptide pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.
Key Takeaways
Female-physiology lens: Semax response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Elevates BDNF and NGF in hippocampus and cortex. Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 300-2000 mcg per dose (varies) 2-4x daily for 10-14 day courses via intranasal; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Cyclical hormone background shapes how women experience Semax. Elevates BDNF and NGF in hippocampus and cortex. Modulates dopamine and serotonin transporter expression. Inhibits enkephalinase, indirectly extending endogenous enkephalin action. Approved in Russia for stroke rehabilitation and cognitive disorders. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, Semax is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
Cyclical and hormonal context
Female physiology is cyclical in a way that male physiology is not, and Semax's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Semax's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
In the perimenopausal window, Semax for cardiovascular (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
Skin Health is one of the dimensions on which women track Semax response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
For autoimmune support in female users, Semax is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
In the perimenopausal window, Semax for cognitive (cycle/menopause) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Intranasal | 300-2000 mcg per dose (varies) | 8–12 weeks on / 4 weeks off |
| Conservative starter | Intranasal | 180-2000 mcg per dose (varies) | 4–6 weeks initial cycle |
| Women's Health focus | Intranasal | 300-2000 mcg per dose (varies) | 2-4x daily for 10-14 day courses |
| Maintenance phase | Intranasal | 210-2000 mcg per dose (varies) | Ongoing with periodic pauses |
Dose timing for Semax is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Semax stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- Semax + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Semax's mechanism in female physiology protocols.
- Semax + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Semax's mechanism in female physiology protocols.
- Semax + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Semax's mechanism in female physiology protocols.
- Semax + Epithalon: Identified by Khavinson in St. Pairs naturally with Semax's mechanism in female physiology protocols.
Excellent tolerability. Mild nasal irritation possible. No dependence.
Lens-specific safety considerations for female physiology use of Semax: Excellent tolerability. Mild nasal irritation possible. No dependence. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How will Semax interact with my cycle?
Best monitoring labs for female users?
Can I use Semax alongside HRT?
Will Semax affect contraceptive efficacy?
What should I look for in Semax sourcing and quality?
What is the standard dosing protocol for Semax?
Start a Semax Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified Semax and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 813 Da
- Sequence length
- 7 aa
- Half-life
- CNS effect hours; plasma minutes
- WADA
- Not on prohibited list
- FDA
- Unapproved (approved in Russia)
- Research
- Multi-decade Russian clinical use
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semax unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for Semax
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised